These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 31857304)

  • 1. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.
    Siafarikas N; Alnæs D; Monereo-Sanchez J; Lund MJ; Selbaek G; Stylianou-Korsnes M; Persson K; Barca ML; Almdahl IS; Fladby T; Aarsland D; Andreassen OA; Westlye LT
    Int Psychogeriatr; 2021 Nov; 33(11):1217-1228. PubMed ID: 34399870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
    Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
    J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric Symptoms and Risk of Progression to Alzheimer's Disease Among Mild Cognitive Impairment Subjects.
    Dietlin S; Soto M; Kiyasova V; Pueyo M; de Mauleon A; Delrieu J; Ousset PJ; Vellas B
    J Alzheimers Dis; 2019; 70(1):25-34. PubMed ID: 31127783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease.
    Siafarikas N; Selbaek G; Fladby T; Šaltytė Benth J; Auning E; Aarsland D
    Int Psychogeriatr; 2018 Jan; 30(1):103-113. PubMed ID: 28927477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
    Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
    Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging.
    Krell-Roesch J; Vassilaki M; Mielke MM; Kremers WK; Lowe VJ; Vemuri P; Machulda MM; Christianson TJ; Syrjanen JA; Stokin GB; Butler LM; Traber M; Jack CR; Knopman DS; Roberts RO; Petersen RC; Geda YE
    Transl Psychiatry; 2019 Mar; 9(1):123. PubMed ID: 30923322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum.
    Wadsworth LP; Lorius N; Donovan NJ; Locascio JJ; Rentz DM; Johnson KA; Sperling RA; Marshall GA
    Dement Geriatr Cogn Disord; 2012; 34(2):96-111. PubMed ID: 22922821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Exploration of Subgroups of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Risks of Conversion to Dementia or Death.
    Qiu J; Goldstein FC; Hanfelt JJ
    Am J Geriatr Psychiatry; 2022 Aug; 30(8):925-934. PubMed ID: 35067420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.
    Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T;
    Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.
    Bensamoun D; Guignard R; Furst AJ; Derreumaux A; Manera V; Darcourt J; Benoit M; Robert PH; David R
    J Alzheimers Dis; 2016; 49(2):387-98. PubMed ID: 26484900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment.
    M FM; Molano A; Castro J; Zarranz JJ
    Curr Alzheimer Res; 2010 Sep; 7(6):517-26. PubMed ID: 20455862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.
    Ramakers IH; Verhey FR; Scheltens P; Hampel H; Soininen H; Aalten P; Rikkert MO; Verbeek MM; Spiru L; Blennow K; Trojanowski JQ; Shaw LM; Visser PJ;
    Psychol Med; 2013 May; 43(5):911-20. PubMed ID: 22954311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum.
    Banning LCP; Ramakers IHGB; Köhler S; Bron EE; Verhey FRJ; de Deyn PP; Claassen JAHR; Koek HL; Middelkoop HAM; van der Flier WM; van der Lugt A; Aalten P; ;
    Am J Geriatr Psychiatry; 2020 Jul; 28(7):735-744. PubMed ID: 32088096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development.
    Burke SL; Maramaldi P; Cadet T; Kukull W
    Arch Gerontol Geriatr; 2016; 65():231-8. PubMed ID: 27111252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.